Stocksigma LogoStocksigma Logo

Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC

Zydus Lifesciences' subsidiary, Zydus Therapeutics, presented post hoc Phase 3 EPICS-III trial data for Saroglitazar in primary biliary cholangitis on 12th

Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC

Zydus Lifesciences Ltd 路 Press Release 路 12 Oct 2026, 11:30 pm

Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC Zydus Lifesciences' subsidiary, Zydus Therapeutics, presented post hoc Phase 3 EPICS-III trial data for Saroglitazar in primary biliary cholangitis on 12th Oct'26. The drug demonstrated superior composite biochemical response versus placebo in both U.S. (60.7% vs. 0%; treatment difference 螖 60.7%) and non-U.S. subgroups (55.1% vs. 13.5%; 螖 41.6%). Saroglitazar was well tolerated and is currently under US FDA review, with Orphan Drug and Fast Track designations. Upon approval, Zydus plans to launch the drug in the U.S. by Mar'27.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements